A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Launched by UCB BIOPHARMA SRL · Sep 24, 2024

Nctid: NCT06617325

Payload: {"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-10-04"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000008180", "term"=>"Lupus Erythematosus, Systemic"}], "ancestors"=>[{"id"=>"D000003240", "term"=>"Connective Tissue Diseases"}, {"id"=>"D000001327", "term"=>"Autoimmune Diseases"}, {"id"=>"D000007154", "term"=>"Immune System Diseases"}], "browseLeaves"=>[{"id"=>"M11177", "name"=>"Lupus Erythematosus, Systemic", "asFound"=>"Systemic Lupus Erythematosus", "relevance"=>"HIGH"}, {"id"=>"M6464", "name"=>"Connective Tissue Diseases", "relevance"=>"LOW"}, {"id"=>"M4629", "name"=>"Autoimmune Diseases", "relevance"=>"LOW"}, {"id"=>"M10200", "name"=>"Immune System Diseases", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Skin and Connective Tissue Diseases", "abbrev"=>"BC17"}, {"name"=>"Immune System Diseases", "abbrev"=>"BC20"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE3"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"QUADRUPLE", "whoMasked"=>["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"PARALLEL"}, "enrollmentInfo"=>{"type"=>"ESTIMATED", "count"=>450}}, "statusModule"=>{"overallStatus"=>"NOT_YET_RECRUITING", "startDateStruct"=>{"date"=>"2024-10-16", "type"=>"ESTIMATED"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2024-09", "completionDateStruct"=>{"date"=>"2027-03-02", "type"=>"ESTIMATED"}, "lastUpdateSubmitDate"=>"2024-09-24", "studyFirstSubmitDate"=>"2024-09-24", "studyFirstSubmitQcDate"=>"2024-09-24", "lastUpdatePostDateStruct"=>{"date"=>"2024-09-27", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"2024-09-27", "type"=>"ACTUAL"}, "primaryCompletionDateStruct"=>{"date"=>"2027-03-02", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48", "timeFrame"=>"Week 48", "description"=>"A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward."}], "secondaryOutcomes"=>[{"measure"=>"Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 24", "timeFrame"=>"Week 24", "description"=>"A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward."}, {"measure"=>"Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 12", "timeFrame"=>"Week 12", "description"=>"A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward."}, {"measure"=>"Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48", "timeFrame"=>"During Treatment Period up to Week 48", "description"=>"Severe BILAG flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A.\n\nDetermination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index."}, {"measure"=>"Achievement of LLDAS in ≥50% of post Baseline visits through Week 48", "timeFrame"=>"During Treatment Period up to Week 48", "description"=>"Low lupus disease activity state (LLDAS) is defined as:\n\n* No significant disease activity as per Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever)\n* No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit\n* Physician's Global Assessment of Disease (PGA) ≤33 mm\n* Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day\n* Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol"}, {"measure"=>"Change from Baseline in SLEDAI-2K at Week 48", "timeFrame"=>"From Baseline (Day 1) to Week 48", "description"=>"SLEDAI-2K measures disease activity. Disease activity in the 30 days prior to and at the time point of the assessment shall be considered. It is a global index and includes 24 clinical symptoms and laboratory variables that are weighted by the type of manifestation, but not by severity or dynamic of the individual item. The total score falls between 0 and 105, with higher scores representing increased disease activity."}, {"measure"=>"Achievement of BILAG 2004 improvement without worsening at Week 48", "timeFrame"=>"Week 48", "description"=>"BILAG 2004 improvement without worsening can be defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B."}, {"measure"=>"Change from Baseline in PGA at Week 48", "timeFrame"=>"From Baseline (Day 1) to Week 48", "description"=>"Physician's Global Assessment of Disease (PGA), the investigator will rate the overall status of the study participant. The PGA of disease activity used will be a 100 mm linear scale without anchors. The very far left end is 'very good, asymptomatic and no limitation of normal activities'; the very far right end indicates 'severe disease'."}, {"measure"=>"Achievement of SRI 4 response at Week 48", "timeFrame"=>"Week 48", "description"=>"The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met):\n\n* Reduction in SLEDAI-2K score of ≥4\n* No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline\n* No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline\n* No worsening in the PGA compared to Baseline score; \"no worsening\" is defined as either no worsening or worsening \\<10% of the full 100 mm visual analog scale (VAS)."}, {"measure"=>"Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48", "timeFrame"=>"During Treatment Period up to Week 48", "description"=>"A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.\n\nA BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system. Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG-2004 index."}, {"measure"=>"Time to severe BILAG flare through Week 48", "timeFrame"=>"During Treatment Period up to Week 48", "description"=>"A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index."}, {"measure"=>"Time to moderate/severe BILAG flare through Week 48", "timeFrame"=>"During Treatment Period up to Week 48", "description"=>"A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.\n\nA BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system.\n\nDetermination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG-2004 index."}, {"measure"=>"Percentage of participants with treatment-emergent adverse events (TEAEs) during the study", "timeFrame"=>"From Baseline (Day 1) until Safety Follow-Up (up to Week 54)", "description"=>"An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication."}, {"measure"=>"Percentage of participants with serious treatment-emergent adverse events during the study", "timeFrame"=>"From Baseline (Day 1) until Safety Follow-Up (up to Week 54)", "description"=>"A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:\n\n1. Results in death\n2. Is life-threatening\n3. Requires inpatient hospitalization or prolongation of existing hospitalization\n4. Results in persistent disability/incapacity\n5. Is a congenital anomaly/birth defect\n6. Is an Important medical event"}, {"measure"=>"Percentage of participants with treatment-emergent adverse events of special interest during the study", "timeFrame"=>"From Baseline (Day 1) until Safety Follow-Up (up to Week 54)", "description"=>"An adverse event of special interest is any adverse event (AE) that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound."}, {"measure"=>"Percentage of participants with treatment-emergent adverse events of special monitoring during the study", "timeFrame"=>"From Baseline (Day 1) until Safety Follow-Up (up to Week 54)", "description"=>"An adverse event of special monitoring is a product-specific adverse event (AE), adverse reaction, or safety topic considered as requiring special monitoring by UCB."}]}, "oversightModule"=>{"oversightHasDmc"=>true, "isFdaRegulatedDrug"=>true, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"keywords"=>["Systemic lupus erythematosus", "Dapirolizumab pegol", "SLE", "DZP"], "conditions"=>["Systemic Lupus Erythematosus"]}, "descriptionModule"=>{"briefSummary"=>"The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["CHILD", "ADULT", "OLDER_ADULT"], "minimumAge"=>"16 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"Inclusion Criteria:\n\n* Study participant must be ≥16 years of age, unless restricted by local regulation, at the time of signing the Informed Consent form (ICF)\n* Study participants who have moderate to severe disease activity due to either persisting active systemic lupus erythematosus (SLE) or due to an acute worsening of SLE in the scope of frequent relapsing-remitting SLE despite stable standard of care(SOC) medication defined as:\n\n a. Diagnosed with SLE at least 24 weeks before the Screening Visit by a qualified physician b. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE c. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following: i) Evidence for anti-dsDNA (defined as evidence for anti-dsDNA antibodies in central laboratory) ii) Either complement C3 \\<lower limit of normal (LLN) OR complement C4 \\<LLN as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:\n 1. Anti-Smith (anti-Sm) antibodies (central laboratory or source verifiable history)\n 2. Anti-Sjögren's syndrome antibody A (Anti-SSA) (Ro)/Anti-Sjögren's syndrome antibody B (anti-SSB) (La) autoantibodies (central laboratory)\n 3. Historical evidence for anti-dsDNA antibodies\n 4. Anti-ribonucleoprotein (RNP) autoantibodies (central laboratory) d. Moderately to severely active defined as:\n\n * British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in ≥2 organ systems and/or a BILAG 2004 Grade A in ≥1 organ systems at Screening and Baseline Visit AND\n * Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 at the Screening Visit AND\n * SLEDAI-2K without labs ≥4 at Baseline Visit e. Receiving the following standard of care (SOC) medications at stable dose:\n * Antimalarial treatment in combination with corticosteroids and/or immunosuppressants or as stand-alone treatment if justified OR\n * Treatment with corticosteroids and/or immunosuppressants if antimalarial treatment is not appropriate (ie, there is documented intolerance in medical history, documented lack of efficacy, contraindications, or lack of availability)\n\n Exclusion Criteria:\n* Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric SLE) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition\n* Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies. This includes systemic reactions due to latex allergy\n* Study participant has a history of malignancy, except the following treated cancers: cervical carcinoma in situ (after complete resection \\[eg, curettage, electrodesiccation\\] not later than 4 weeks prior to the Screening Visit \\[V1\\]), basal cell carcinoma, or dermatological squamous cell carcinoma\n* Study participant has an increased risk for thromboembolic events due to an ongoing heart disease or due to a medical device, including but not limited to vascular graft, valvular heart disease, atrial fibrillation, or a heart rhythm disorder\n* Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE\n* Study participant has evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study\n* Study participant has clinically significant active or latent infection\n* Study participant had a reactivated latent infection (eg, cytomegalovirus, herpes simplex virus, or herpes zoster infection) or opportunistic infection (including but not limited to, pneumocystis, cytomegalovirus, or severe herpes zoster infection) within 12 weeks prior to the first study medication infusion (Visit 2) or is currently receiving suppressive therapy for an opportunistic infection\n* Study participants who have received live/live attenuated vaccines within 6 weeks prior to the first study medication infusion\n* Study participant has used the prohibited medications defined in the Protocol\n* Study participant has previously been randomized within this study or has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP\n* Study participant has participated in another study of an investigational medicinal product (IMP) within the previous 12 weeks or 5 half-lives of the IMP whatever is longer, or is currently participating in another study of an IMP\n* Study participant has chronic kidney failure stage 4, manifested by estimated glomerular filtration rate (eGFR) \\<30 mL/min/1.73m2, or serum creatinine \\>2.5 mg/dL, or participant has proteinuria \\>3g/day, or protein:creatinine ratio \\>340 mg/mmol at the Screening Visit"}, "identificationModule"=>{"nctId"=>"NCT06617325", "acronym"=>"PHOENYCS FLY", "briefTitle"=>"A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus", "organization"=>{"class"=>"INDUSTRY", "fullName"=>"UCB Pharma"}, "officialTitle"=>"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus", "orgStudyIdInfo"=>{"id"=>"SL0044"}, "secondaryIdInfos"=>[{"id"=>"2019-003407-35", "type"=>"EUDRACT_NUMBER"}, {"id"=>"2023-508191-11", "type"=>"REGISTRY", "domain"=>"EU CT Number"}, {"id"=>"U1111-1298-3467", "type"=>"OTHER", "domain"=>"WHO universal trial number (UTN)"}]}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"Dapirolizumab pegol", "description"=>"Study participants will receive dapriolizumab pegol throughout the Treatment Period.", "interventionNames"=>["Drug: DZP"]}, {"type"=>"PLACEBO_COMPARATOR", "label"=>"Placebo", "description"=>"Study participants will receive placebo throughout the Treatment Period.", "interventionNames"=>["Other: Placebo"]}], "interventions"=>[{"name"=>"DZP", "type"=>"DRUG", "otherNames"=>["CDP7657"], "description"=>"Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.", "armGroupLabels"=>["Dapirolizumab pegol"]}, {"name"=>"Placebo", "type"=>"OTHER", "otherNames"=>["PBO"], "description"=>"Study participants will receive placebo at prespecified time-points.", "armGroupLabels"=>["Placebo"]}]}, "contactsLocationsModule"=>{"centralContacts"=>[{"name"=>"UCB Cares", "role"=>"CONTACT", "email"=>"ucbcares@ucb.com", "phone"=>"1-844-599-2273"}, {"name"=>"UCB Cares", "role"=>"CONTACT", "phone"=>"001 844 599 2273"}], "overallOfficials"=>[{"name"=>"UCB Cares", "role"=>"STUDY_DIRECTOR", "affiliation"=>"001 844 599 2273 (UCB)"}]}, "ipdSharingStatementModule"=>{"url"=>"https://www.Vivli.org", "infoTypes"=>["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame"=>"Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.", "ipdSharing"=>"YES", "description"=>"Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.", "accessCriteria"=>"Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal."}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"UCB Biopharma SRL", "class"=>"INDUSTRY"}, "responsibleParty"=>{"type"=>"SPONSOR"}}}}